Results 81 to 90 of about 176,716 (160)

CDK4/6 inhibitor ribociclib and doxorubicin combination treatment inhibits breast cancer bone metastasis and enhances T-cell targeted therapy. [PDF]

J Bone Oncol
Su X, Kobayashi T, Xiang J, Xu Y, Shajahan-Haq AN, Mardani M, Noordeen S, O'Donnell K, Kwakwa KA, Guan D, Fox GC, Fontana F, Cybulla E, Bakewell S, Vindigni A, Veis DJ, Achilefu S, Lanza GM, Weilbaecher KN.   +18 more
europepmc   +1 more source

L-Arginine as an Adjuvant Chemosensitizer: Enhancement of Intestinal Permeability and Cytotoxic Activity of Doxorubicin. [PDF]

Pharmaceuticals (Basel)
Saad G, Alquwayi RM, Alanazi HB, Aldahmashi FB, Alahmary AM, Almutairi SK, Alshammari FR, Alshammari GT, Alrashidi AJ, Aldousari NK, Alsubiei HF, Alanazi LH, Aldossary MH, Sultan AA.   +13 more
europepmc   +1 more source

Molecular docking, synthesis, and cytotoxic evaluation of novel quinazoline-quinazolinone hybrid compounds. [PDF]

Res Pharm Sci
Azarmi M, Rahimi S, Hormozi M, Rezaeinasab R.   +3 more
europepmc   +1 more source

Identification of a <i>TOP3A</i> genetic variant as a novel biomarker for sensitivity to doxorubicin. [PDF]

Front Pharmacol
Takacova T, Schirmer MA.
europepmc   +1 more source

Alternative Splicing of the NF-Y Subunit, NF-YA, in Neuroblastoma Phenotype Heterogeneity. [PDF]

Cancers (Basel)
Martelli I, Cappabianca LA, Sbaffone M, Farina AR, Mackay AR.   +4 more
europepmc   +1 more source

Correction: EZH2 blockade reverses doxorubicin resistance by inducing metabolic vulnerability and enhancing DNA damage in breast cancer. [PDF]

Front Pharmacol
Wang X, Ding Y, Mai Y, Li R, Shao X, Chen W, Li Y, Liu L, Wang H, Liu K, Niu Y, Li J, Xu G, Zhao Y.   +13 more
europepmc   +1 more source

Emerging Nanocarrier Strategies for Optimized Drug Delivery in the Treatment of Primary Bone Cancer. [PDF]

Oncol Res
Ngema LM, Adeyemi SA, Choonara YE.
europepmc   +1 more source

Resistance to doxorubicin therapy in breast cancer cells could be attenuated by ligustilide: impact on autophagy and LncRNA H19. [PDF]

BMC Complement Med Ther
Amr EA, El-Feky OA, Khedr EG, El-Ashmawy NE.   +3 more
europepmc   +1 more source

Betulinic acid is associated with miR-21 modulation, apoptosis and redox changes in breast cancer cells: an in vitro and in silico study. [PDF]

Sci Rep
Mahmoud MA, Abdo H, Mekky M, Salem T, Mabrouk S, Khaled B.   +5 more
europepmc   +1 more source